The Coronavirus Is No Match Against Sybody 23

The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 receptor. Unsurprisingly, stopping the spike protein from latching on to ACE2 has been a major focus in the design and development of COVID-19 therapeutics.

One such approach is by using antibodies (natural immune molecules that attach to pathogens) which have proven to be…

--

--

--

Follow me for bite-sized stories on the latest discoveries and innovations in biomedical research.

Love podcasts or audiobooks? Learn on the go with our new app.

Recommended from Medium

Event cancelled better than life cancelled, says WHO

COVID-19 in NC: Hospital patient count climbs for 11th straight day; new case average rises past…

Patient 0.

COVID-19 ELISA, A SUPERIOR AND STATE OF THE ART TESTING METHOD

A Venture into Viruses

Biovac first in Africa to use mRNA technology

A follow up.

The Plague-Ground — Virus and Vaccine: Charting our death and resurrection

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
River D'Almeida, Ph.D

River D'Almeida, Ph.D

Follow me for bite-sized stories on the latest discoveries and innovations in biomedical research.

More from Medium

Fat Burning Lessons From Fruit Flies

The Implications Of Clotting In A Heart Attack

Replacing Microglia to Slow Down Neurodegenerative Disease

Why Mucus-Eating Bacteria Stimulate a Healthy Gut